Retraction Notice to: mTORC1-Induced HK1-Dependent Glycolysis Regulates NLRP3 Inflammasome Activation (Cell Reports (2015) 12(1) (102–115), (S2211124715005823), (10.1016/j.celrep.2015.05.046));MTORC1-Induced HK1-Dependent Glycolysis Regulates NLRP3 Inflammasome Activation

Cell Reports

Volumn 12, Issue 1, 2015, Pages 102-115

  Moon, Jong Seok ^a,b   Hisata, Shu ^a,b   Park, Mi Ae ^c   DeNicola, Gina M ^a   Ryter, Stefan W ^a,b   Nakahira, Kiichi ^a,b   Choi, Augustine M K ^a,b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CRYOPYRIN; HEXOKINASE 1; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; LIPOPOLYSACCHARIDE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; CARRIER PROTEIN; HEXOKINASE; HK1 PROTEIN, MOUSE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; NLRP3 PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; GLYCOLYSIS; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; TRANSLATION REGULATION; ANIMAL; CELL CULTURE; METABOLISM;

MAMMALIA;

ANIMALS; CARRIER PROTEINS; CASPASE 1; CELLS, CULTURED; GLYCOLYSIS; HEXOKINASE; INFLAMMASOMES; INTERLEUKIN-1BETA; MACROPHAGES; MICE; MULTIPROTEIN COMPLEXES; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; TOR SERINE-THREONINE KINASES;

EID: 84937513657     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2023.112639     Document Type: Erratum

References (50)

1. Arora K.K., Fanciulli M., Pedersen P.L. Glucose phosphorylation in tumor cells. Cloning, sequencing, and overexpression in active form of a full-length cDNA encoding a mitochondrial bindable form of hexokinase. J.Biol. Chem. 1990, 265:6481-6488.
2. Azoulay-Zohar H., Aflalo C. Binding of rat brain hexokinase to recombinant yeast mitochondria: identification of necessary molecular determinants. J.Bioenerg. Biomembr. 1999, 31:569-579.
3. Azoulay-Zohar H., Aflalo C. Binding of rat brain hexokinase to recombinant yeast mitochondria: identification of necessary physico-chemical determinants. Eur. J. Biochem. 2000, 267:2973-2980.
4. Baijal M., Wilson J.E. Residues putatively involved in binding of ATP and glucose 6-phosphate to a mammalian hexokinase: site-directed mutation at analogous positions in the N- and C-terminal halves of the type I isozyme. Arch. Biochem. Biophys. 1995, 321:413-420.
5. Benjamin D., Colombi M., Moroni C., Hall M.N. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug Discov. 2011, 10:868-880.
6. Bruchard M., Mignot G., Derangère V., Chalmin F., Chevriaux A., Végran F., Boireau W., Simon B., Ryffel B., Connat J.L., et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat. Med. 2013, 19:57-64.
7. Bustamante E., Morris H.P., Pedersen P.L. Energy metabolism of tumor cells. Requirement for a form of hexokinase with a propensity for mitochondrial binding. J.Biol. Chem. 1981, 256:8699-8704.
8. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11:85-95.
9. Crane R.K., Sols A. The association of hexokinase with particulate fractions of brain and other tissue homogenates. J.Biol. Chem. 1953, 203:273-292.
10. DeBerardinis R.J., Lum J.J., Hatzivassiliou G., Thompson C.B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008, 7:11-20.
11. Deberardinis R.J., Sayed N., Ditsworth D., Thompson C.B. Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev. 2008, 18:54-61.
12. Düvel K., Yecies J.L., Menon S., Raman P., Lipovsky A.I., Souza A.L., Triantafellow E., Ma Q., Gorski R., Cleaver S., et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 2010, 39:171-183.
13. Elstrom R.L., Bauer D.E., Buzzai M., Karnauskas R., Harris M.H., Plas D.R., Zhuang H., Cinalli R.M., Alavi A., Rudin C.M., Thompson C.B. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004, 64:3892-3899.
14. Everts B., Amiel E., Huang S.C.-C., Smith A.M., Chang C.-H., Lam W.Y., Redmann V., Freitas T.C., Blagih J., van der Windt G.J.W., et al. TLR-driven early glycolytic reprogramming via the kinases TBK1-IKKe{open} supports the anabolic demands of dendritic cell activation. Nat. Immunol. 2014, 15:323-332.
15. Franchi L., Eigenbrod T., Muñoz-Planillo R., Nuñez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat. Immunol. 2009, 10:241-247.
16. Fueger P.T., Heikkinen S., Bracy D.P., Malabanan C.M., Pencek R.R., Laakso M., Wasserman D.H. Hexokinase II partial knockout impairs exercise-stimulated glucose uptake in oxidative muscles of mice. Am. J. Physiol. Endocrinol. Metab. 2003, 285:E958-E963.
17. Greiner E.F., Guppy M., Brand K. Glucose is essential for proliferation and the glycolytic enzyme induction that provokes a transition to glycolytic energy production. J.Biol. Chem. 1994, 269:31484-31490.
18. Henao-Mejia J., Elinav E., Jin C., Hao L., Mehal W.Z., Strowig T., Thaiss C.A., Kau A.L., Eisenbarth S.C., Jurczak M.J., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482:179-185.
19. Jourdan T., Godlewski G., Cinar R., Bertola A., Szanda G., Liu J., Tam J., Han T., Mukhopadhyay B., Skarulis M.C., et al. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat. Med. 2013, 19:1132-1140.
20. Kim D.H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., Erdjument-Bromage H., Tempst P., Sabatini D.M. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002, 110:163-175.
21. Koppenol W.H., Bounds P.L. The Warburg effect and metabolic efficiency: re-crunching the numbers. Science 2009, 22:1029-1033.
22. Krawczyk C.M., Holowka T., Sun J., Blagih J., Amiel E., DeBerardinis R.J., Cross J.R., Jung E., Thompson C.B., Jones R.G., Pearce E.J. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood 2010, 115:4742-4749.
23. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
24. Latz E., Xiao T.S., Stutz A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 2013, 13:397-411.
25. Levine A.J., Puzio-Kuter A.M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010, 330:1340-1344.
26. Ma X.M., Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 2009, 10:307-318.
27. Marçais A., Cherfils-Vicini J., Viant C., Degouve S., Viel S., Fenis A., Rabilloud J., Mayol K., Tavares A., Bienvenu J., et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat. Immunol. 2014, 15:749-757.
28. Masters S.L., Dunne A., Subramanian S.L., Hull R.L., Tannahill G.M., Sharp F.A., Becker C., Franchi L., Yoshihara E., Chen Z., et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat. Immunol. 2010, 11:897-904.
29. Mathupala S.P., Ko Y.H., Pedersen P.L. Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin. Cancer Biol. 2009, 19:17-24.
30. Nakahira K., Haspel J.A., Rathinam V.A.K., Lee S.-J., Dolinay T., Lam H.C., Englert J.A., Rabinovitch M., Cernadas M., Kim H.P., et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat. Immunol. 2011, 12:222-230.
31. Parry D.M., Pedersen P.L. Intracellular localization of rat kidney hexokinase. Evidence for an association with low density mitochondria. J.Biol. Chem. 1984, 259:8917-8923.
32. Pelicano H., Martin D.S., Xu R.H., Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006, 25:4633-4646.
33. Richter J.D., Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 2005, 433:477-480.
34. Rowe I., Chiaravalli M., Mannella V., Ulisse V., Quilici G., Pema M., Song X.W., Xu H., Mari S., Qian F., et al. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat. Med. 2013, 19:488-493.
35. Sarbassov D.D., Ali S.M., Kim D.H., Guertin D.A., Latek R.R., Erdjument-Bromage H., Tempst P., Sabatini D.M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 2004, 14:1296-1302.
36. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
37. Stienstra R., van Diepen J.A., Tack C.J., Zaki M.H., van de Veerdonk F.L., Perera D., Neale G.A., Hooiveld G.J., Hijmans A., Vroegrijk I., et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc. Natl. Acad. Sci. USA 2011, 108:15324-15329.
38. Subramanian N., Natarajan K., Clatworthy M.R., Wang Z., Germain R.N. The adaptor MAVS promotes NLRP3 mitochondrial localization and inflammasome activation. Cell 2013, 153:348-361.
39. Sutterwala F.S., Ogura Y., Szczepanik M., Lara-Tejero M., Lichtenberger G.S., Grant E.P., Bertin J., Coyle A.J., Galán J.E., Askenase P.W., Flavell R.A. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 2006, 24:317-327.
40. Tannahill G.M., Curtis A.M., Adamik J., Palsson-McDermott E.M., McGettrick A.F., Goel G., Frezza C., Bernard N.J., Kelly B., Foley N.H., et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature 2013, 496:238-242.
41. Thoreen C.C., Kang S.A., Chang J.W., Liu Q., Zhang J., Gao Y., Reichling L.J., Sim T., Sabatini D.M., Gray N.S. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J.Biol. Chem. 2009, 284:8023-8032.
42. Tsukiyama-Kohara K., Poulin F., Kohara M., DeMaria C.T., Cheng A., Wu Z., Gingras A.-C., Katsume A., Elchebly M., Spiegelman B.M., et al. Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1. Nat. Med. 2001, 7:1128-1132.
43. Vandanmagsar B., Youm Y.-H., Ravussin A., Galgani J.E., Stadler K., Mynatt R.L., Ravussin E., Stephens J.M., Dixit V.D. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 2011, 17:179-188.
44. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
45. Wen H., Gris D., Lei Y., Jha S., Zhang L., Huang M.T., Brickey W.J., Ting J.P. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 2011, 12:408-415.
46. Wilson J.E. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J.Exp. Biol. 2003, 206:2049-2057.
47. Yang K., Shrestha S., Zeng H., Karmaus P.W., Neale G., Vogel P., Guertin D.A., Lamb R.F., Chi H. T cell exit from quiescence and differentiation into Th2 cells depend on Raptor-mTORC1-mediated metabolic reprogramming. Immunity 2013, 39:1043-1056.
48. Zeng H., Yang K., Cloer C., Neale G., Vogel P., Chi H. mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature 2013, 499:485-490.
49. Zhou R., Tardivel A., Thorens B., Choi I., Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 2010, 11:136-140.
50. Zhou R., Yazdi A.S., Menu P., Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011, 469:221-225.